trans-Nerolidol
CAS No. : 40716-66-3
| Size | Price | Stock |
|---|---|---|
| 500g | $134 | In-stock |
| 1 kg | Get quote | |
| 2 kg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N6635 |
| M.Wt: | 222.37 |
| Formula: | C15H26O |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (DOX) (HY-15142A) against intestinal cancer and breast cancer cells in vitro. trans-Nerolidol increases accumulation of DOX inside cells in vitro. trans-Nerolidol activates apoptosis in vivo[1].
In Vitro:trans-Nerolidol (Compound NER) (5-500 μM, 72 h) shows a mild synergistic effect on DOX (0.1-3 μM) efficacy in MDA-MB-231 breast cancer cell lines and mildly antagonistic effect when combined with DOX in MCF7 cells[1].
trans-Nerolidol (1 μM, 24 h) significantly inhibits cell migration alone and has stronger anti-migration effect when combined with DOX (2 μM) in MDA-MB-231 cells[1].
trans-Nerolidol (25 μg/mL) suppresses the expression of phosphor-FAK (Tyr397) while CD44 expression is elevated when combined with DOX (0.038 μM) in MDA-MB-231 cells[1].
In Vivo:trans-Nerolidol (Compound NER) (50-100 mg/kg, p.o., three single doses on day 1, 4, 7) increases the phosphorylated form of p53 when combined with DOX (3 mg/kg, i.v.) in immunocompetent NMRI mice implanted with EST cancer cells[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- trans-Nerolidol
- Cat. No.:
- HY-N6635
- Quantity:
Your information is safe with us.